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Summary
Objective: To determine whether cytokine polymorphisms are associated with leprosy and/or
their subtypes in a Brazilian population.
Methods: Genotyping using polymerase chain reaction with sequence-specific primers (PCR-SSP)
was performed for: TNF308/238, IL2330/+166, IL6174, IFNG+874, TGFB1+869/+915, and IL10592/
819/1082 in 240 healthy controls and 167 patients with leprosy.
Results: For TNF308, a higher frequency of GG genotype (85.5% vs. 74.1% in healthy controls,
p = 0.009), along with a decreased frequency of GA/AA genotypes was observed among leprosy
patients as compared to the control group (14.5% vs. 25.9%, p = 0.009). The GG genotype was
particularly higher in patients with tuberculoid (TT) and borderline (BB) leprosy (90.5% and 89.8%,
respectively). Analysis of IL10 genotypes revealed a lower frequency of GCC/GCC haplotype in
lepromatous leprosy (LL) patients (6.2%) in comparison to controls (15.4%).
Conclusion: It is suggested that the G!A substitution at position 308 in the TNF promoter
region plays an important role in leprosy patients.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Tel.: +55 44 3261 4864;
fax: +55 44 3261 4931.
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Leprosy, caused by the obligate intracellular microorganism
Mycobacterium leprae, is a chronic infectious disease still
considered a major health problem in some countries of
Africa, Asia, and Latin America. According to the WorldPublished by Elsevier Ltd. All rights reserved.
494 D.S.A. Franceschi et al.Health Organization, approximately 260 000 new patients
were affected in 2006.1
The disease causes skin lesions and neuropathy. Secondary
complications of the neuropathy can result in deformity and
disability. Damage development in leprosy individuals is
normally caused by host immune responses driven to myco-
bacterial elimination.2
The Ridley—Jopling classification of leprosy is based on
clinical and histopathological criteria, which suggest a dis-
ease spectrum with five clinical categories: tuberculoid (TT),
borderline tuberculoid (BT), borderline borderline (BB), bor-
derline lepromatous (BL), and lepromatous (LL) leprosy.3 At
one pole, TT leprosy consists in few well-defined skin
patches, few bacilli (paucibacillary), and vigorous cell-
mediated immunity (CMI). At the other pole, LL leprosy
presents many skin lesions with uncontrolled proliferation
of leprosy bacilli (multibacillary) and inefficient CMI.4 Bor-
derline leprosy (BB) manifests clinical and immunological
features with characteristics between the two forms.5
There is high Th1 cytokine production in skin lesions of
paucibacillary patients (TT), like interferon-g (IFN-g), inter-
leukin (IL)-2, IL-7, IL-12, IL-15, and IL-18, characteristic of
intense CMI. Infected macrophages are activated by IFN-g,
and IL-2 induces clonal expansion of activated Tcells, leading
to an enhanced production of IFN-g,6 also seen in natural
killer (NK) cells stimulated by IL-12.7 Autocrinous macro-
phage tumor necrosis factor-a (TNF-a) production acts syner-
gically working for Th1 pattern maintenance.8 IFN-g, in
synergy with TNF-a, activates infected macrophages,
thereby initiating a major effector mechanism of CMI.
Multibacillary patients (LL and BB) present a Th2 cytokine
pattern (transforming growth factor-b1 (TGF-b1), IL-4, IL-5,
and IL-10) in local skin lesions, indicating elevated antibody
production, but inefficient CMI.9 An immunosuppressive
effect conferred by IL-4 can lead to mycobacterial prolifera-
tion, inhibiting monocyte and Tcell activation,10 and chronic
local IL-10 release differentiates CD4+ Tcells in a regulatory T
cell subpopulation, acting in antigen-specific immunosup-
pression.11 TGF-b, an activated monocyte product, inhibits
IFN-g and IL-2 expression, permitting disease progression by
the lack of macrophage cytotoxicity.12
Single nucleotide polymorphisms (SNPs) are considered
the most abundant source of genomic variation in humans,
and differences in coded protein structure can be caused
when these are present in genes.13 Some SNPs have been
described that may be important factors in leprosy suscept-
ibility and outcome.14—22 The aim of this study was to inves-
tigate if some cytokine SNPs are involved in the pathogenesis
of leprosy and its subtypes.
Methods
Patients and controls
A total of 167 leprosy patients (96 males, 71 females), of
mixed ethnicity, undergoing treatment at Centro de Espe-
cialidades do Sistema U´nico de Sau´de (SUS) in the cities of
Maringa´, Sarandi, and Umuarama, state of Parana´, Brazil,
were enrolled in this study between 2005 and 2007. Approval
for human study protocols was obtained from the human
subject review boards at the Universidade Estadual de Mar-
inga´ in southern Brazil.Patients were classified into four distinct groups according
to clinical and laboratory observations for leprosy diagnosis.
Of the total patients, 43 (25.7%) were diagnosed to have TT
leprosy, 65 (38.9%) LL leprosy, and 50 (29.9%) BB leprosy; nine
(5.4%) were diagnosed with an indeterminate form of the
disease.
Two hundred forty individuals (133 males, 107 females)
without any history of mycobacterial infection and
belonging to the same geographical region as the patients
were included as healthy controls. These individuals
were of mixed ethnic background. The mean age of
patients was 46.0  14.8 years and of controls was
35.6  10.7 years.
The population of Brazil is made up of genetically hetero-
geneous groups, formed mainly by European explorers, set-
tlers, and immigrants, mixed with native Amerindians and
African slaves.23 The sample was considered to be of mixed
ethnic groups because, according to Parra et al. (2003),24
in Brazil, at an individual level, skin color determined by
physical evaluation is a poor predictor of genomic African
ancestry.
Genotyping of SNPs for cytokine genes
Genomic DNA extraction was performed by EZ-DNA kit (Bio-
logical Industries, Beit Haemek, Israel) or Neoscience kit
(One Lambda Inc., San Diego, CA, USA) using 150 ml of
buffy-coat. DNA samples were stored in a freezer at
20 8C until use. After DNA concentration adjustment
(25—200 ng/ml), sequence-specific primer PCR (PCR-SSP;
One Lambda Cytokine Genotyping Primer Pack, One Lambda,
CA, USA) was performed for genotyping of the following SNPs:
TNF308 (G!A), IL6174 (G!C), IFNG+874 (T!A), TGFB1+869
(T!C) and TGFB1+915 (G!C), and IL10592 (G!C), IL10819
(C!T), and IL101082 (G!A) according to manufacturer’s
instructions. Genotyping of TNF238 (G!A), IL2330
(T!G), and IL2+166 (G!T) was performed using a kit devel-
oped in house.25 Amplified product was transferred in 2.5%
agarose gel and electrophoresed at 150 V for 9 min approxi-
mately.
Statistical analysis
Allele frequencies were obtained through direct counting.
Chi-square tests with Yate’s correction or Fisher’s exact tests
were carried out to analyze disease association using Graph-
Pad Software (San Diego, CA, USA; http://www.graphpad.-
com/quickcalcs/contingency1.cfm). Odds ratios (OR) with
95% confidence intervals (95% CI) were calculated using SISA
statistics online (available at: http://www.quantitatives-
kills.com/sisa/). A p-value of 0.05 was considered to be
statistically significant. Hardy—Weinberg equilibrium was
tested for each SNP using Arlequin software version 3.1
(http://cmpg.unibe.ch/software/arlequin3/).
Finally, the observed p-values were corrected by means of
the Bonferroni correction to enable multiple comparisons.
Since six independent regions were investigated (chromo-
some 1 IL10 region, chromosome 4 IL2 region, chromosome 6
TNF region, chromosome 7 IL6 region, chromosome 12 IFNG
region, and chromosome 19 TGFB1 region), the corrected p-
value was six times the observed p-value.
Table 1 Cytokine genotypes and frequencies in leprosy patients and controls in a population from the south of Brazil.
SNP Genotype Leprosy n (%) Controls n (%) p-Value
TNF238 N = 167 N = 219
G/G 147 (88.0) 192 (87.7) 0.96
G/A or A/A 20 (12.0) 27 (12.3)
IFNG+874 N = 164 N = 240
T/T 28 (17.1) 33 (13.8) 0.44
T/A 80 (48.8) 131 (54.6) 0.29
A/A 56 (34.1) 76 (31.6) 0.68
IL6174 N = 164 N = 240
C/C 18 (11.0) 21 (8.8) 0.57
G/G or G/C 146 (89.0) 219 (91.3)
IL2330 N = 167 N = 219
T/T 93 (55.7) 108 (49.3) 0.25
T/G or G/G 74 (44.3) 111 (50.7)
IL2+166 N = 167 N = 219
G/G 77 (46.1) 113 (51.6) 0.33
G/T or T/T 90 (53.9) 106 (48.4)
IL101082/819/592 N = 165 N = 240
ACC/ACC or ACC/ATA or ATA/ATA 78 (47.3) 95 (39.6) 0.43
GCC/ACC or GCC/ATA 67 (40.6) 108 (45) 0.44
GCC/GCC 20 (12.1) 37 (15.4) 0.15
TGFB1+869/+915 N = 164 N = 238
CG/CC or CC/CC or TC/TC or TC/CC 13 (7.9) 12 (5.0) 0.33
TG/CC or CG/CG or TG/TC 37 (22.6) 58 (24.4) 0.53
TG/TG or TG/CG 114 (69.5) 168 (70.6) 0.90
SNP, single nucleotide polymorphism.
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Association between TNF308 GA/AA genotypes
and leprosy
The cytokine genotypes and frequencies in the leprosy
patients and control group, sampled in the south of Brazil,
are shown in Table 1. The genotype frequency distribution
was in Hardy—Weinberg equilibrium. None of the cytokine
genes showed a significant difference between leprosy
patients and controls except for the TNF308 polymorphism
(Table 2).
A significantly higher frequency of GG genotype was
observed in leprosy patients per se (85.5%) compared to
healthy controls (74.1%) ( p = 0.009, OR = 2.06, 95% CI
1.22—3.46). Similarly, a decreased frequency of TNF308Table 2 Genotype and allelic frequencies of TNF308 single nucleo
a population from the south of Brazil.
TNF308 Leprosy Controls p-Valu
N = 165 N = 239
G/G 141 (85.5) 177 (74.1) 0.009
G/A or A/A 24 (14.5) 62 (25.9) 0.009
G 304 (92.1) 414 (86.6) 0.02
A 26 (7.9) 64 (13.4) 0.02
Results are n (%). OR, odds ratio; 95% CI, 95% confidence interval.GA/AA genotypes was observed among patients (14.5%) in
comparison to the control group (25.9%) ( p = 0.009,
OR = 0.48, 95% CI 0.29—0.82). After Bonferroni correction,
these results remained statistically significant ( p = 0.05).
Therefore, the allelic frequency of TNF308A was signifi-
cantly higher in the control group (13.4%) than in the leprosy
patients (7.9%) ( p = 0.02, OR = 0.55, 95% CI 0.34—0.89),
although this difference was not significant after correction.
No significant differences were found in TNF308 GG
genotype frequencies among the leprosy subgroups
(Table 3). The analysis revealed that TT, BB, and LL patients
presented high frequencies of TNF308 GG genotype (90.5%,
89.8%, and 81.5%, respectively) and decreased GA/AA fre-
quencies (9.5% TT patients and 10.2% BB patients) in com-
parison to healthy individuals (74.1% GG and 25.9% GA/AA).
However, the p-value for LL patients did not reach signifi-tide polymorphism in leprosy patients and control individuals in
e OR 95% CI Corrected p-value
2.06 1.22—3.46 0.05
0.48 0.29—0.82 0.05
1.81 1.12—2.92 0.12
0.55 0.34—0.89 0.12
Table 3 TNF and IL10 gene frequencies for subgroups of leprosy and controls in a population from the south of Brazil.
SNP LL TT BB Controls
TNF308 N = 65 N = 42 N = 49 N = 239
GG 53 (81.5) 38 (90.5) a 44 (89.8)a 177 (74.1)a
GA or AA 12 (18.5) 4 (9.5)b 5 (10.2)b 62 (25.9)b
IL101082/819/592 N = 65 N = 42 N = 49 N = 240
ACC/ACC or ACC/ATA or ATA/ATA 33 (50.8) 15 (35.7) 26 (53.1) 95 (39.6)
GCC/ACC or GCC/ATA 28 (43.0) 21 (50) 16 (32.6) 108 (45)
GCC/GCC 4 (6.2)c 6 (14.3) 7 (14.3) 37 (15.4) c
Results are n (%). SNP, single nucleotide polymorphism; LL, lepromatous leprosy, TT, tuberculoid leprosy; BB, borderline leprosy.
a TT vs. controls, p-value = 0.009, OR = 3.33 (1.14—9.70), corrected p-value = 0.05; BB vs. controls, p-value = 0.03, OR = 3.08 (1.17—8.12),
corrected p-value = 0.17.
b TT vs. controls, p-value = 0.009, OR = 0.30 (0.10—0.88), corrected p-value = 0.05; BB vs. controls, p-value = 0.03 OR = 0.32 (0.12—0.86),
corrected p-value = 0.17.
c LL vs. controls, p-value = 0.02, corrected p-value = 0.12.
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difference after Bonferroni correction (corrected p-
value = 0.05).
Association between IL10 genotypes and leprosy
Analysis of IL10 genotypes did not show any significant dif-
ferences between leprosy patients and controls. When each
subgroup was considered separately (Table 3), a lower fre-
quency of IL101082G/819C/592C haplotype was found in LL
patients (6.2%) in comparison to controls (15.4%) ( p = 0.02).
However, after accounting for multiple testing this result was
no longer significant (corrected p-value = 0.12).
Association between other SNPs and leprosy
No association was found between any other SNP and the
leprosy subgroups. No significant differences were found in
the comparison of genotypes according to gender (data not
shown).
Discussion
The present study shows a positive association between the
TNF308 GG genotype and leprosy per se, and a negative
association with TNF308 GA/AA. Previous studies have shown
associations between susceptibility to leprosy or leprosy
subtypes and polymorphisms in cytokine gene regions. An
early report conducted by Shaw et al.15 in a Brazilian cohort
suggested that TNF2/LTA2 haplotypes confer a protective
effect against leprosy. Also in Brazilian patients, Santos
et al.16 found that the presence of TNF2 had a protective
effect in leprosy patients per se compared to a control group.
However, contradictory results have been found in other
studies. Roy et al.,14 studying Indian patients, found that
the frequency of TNF2 was higher in lepromatous patients
than in healthy individuals. This result was similar to the
observations of Vejbaesya et al.22 in leprosy patients from
Thailand, which showed this SNP to be involved in suscept-
ibility to the multibacillary form of the infection.
These contradictory findings are mainly due to ethnic
differences. Differences in the allelic constitutions of these
populations may be strongly involved in the direction of theassociation. With regard to allelic frequencies in control
subjects, it can be seen that the presence of the TNF308A
allele is lower in Asian studies (2.8% and 4.6%) while being
constitutively elevated in the Brazilian control groups of the
present study (13.4%) and the Santos study (16.3%). Such
constitutive differences in frequencies may be able to
explain why Brazilian studies showed negative associations
of the A allele to leprosy and Asian studies observed positive
associations.
With regard to the issue of TNF-a production being
affected by these polymorphisms, it is unclear at the
moment if the TNF G!A substitution in serum levels of this
cytokine plays a role. Some studies have failed to associate
the presence of the A allele with different levels of TNF-a
production, while other attempts have found that a G!A
substitution at the 308 position is a much stronger tran-
scriptional activator than the common GG allele, which is
associated with lower production (reviewed by Bayley
et al.).26 Moraes et al.,27 in a study on BT leprosy patients
using the Mitsuda test, found that TNF308 G!A patients
showed greater induration sizes compared to TNF308 GG
patients, when neither group showed reverse reactions and
had not been exposed to the BCG vaccine, suggesting higher
levels of TNF-a in BT patients with G!A substitution. In
addition, Vanderborght et al. (2007)28 found that patients
with the presence of the A allele in the 308 TNF promoter
region exhibited lower bacteriological indices. One hypoth-
esis is that this direct effect on gene regulation probably
results in dissemination of bacilli by weak macrophage
activation, which is dependent on TNF-a, resulting in sus-
ceptibility to M. leprae infection. Elevated frequencies of
the GG genotype could be a reflex of diminished GA/AA
frequencies or could be related to a lower TNF-a release
potential.
This present study did not find an association of238 G!A
substitution with leprosy per se or subgroups, found in other
studies.16,22 The exact influence of the TNF238 G/A variant
on the TNF-a function and expression is not yet fully under-
stood, although the localization of this polymorphism is in the
regulatory region.29,30 The issue is further complicated
because these polymorphisms may be in linkage disequili-
brium with themselves and as a part of extended haplotypes,
including LTA and classes I and II HLA alleles, found in the
same chromosome 6.15
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arranged to form haplotypes in the promoter gene, and these
combinations have been associated with secretion of the
cytokine in vitro.31—33
In this study, the occurrence of the
IL101082G/819C/592C haplotype was not associated to an
outcome of leprosy. Although lepromatous patients showed
lower frequencies of this haplotype compared to control
individuals, the statistical significance of this negative asso-
ciation was lost after correction for multiple comparisons.
In Indian patients, the presence of the 3575T/2849G/
2763C/1082A/819C/592C haplotype conferred resis-
tance to leprosy per se and the 3575T/2849G/2763C/
1082A/819T/592A haplotype was associated to devel-
opment of the severe form of leprosy.19 In another Brazilian
study, IL10819 TTwas increased in leprosy patients per se as
compared to controls,16 which could not be confirmed in this
research.
According to Moraes et al. (2004),18 the extended haplo-
type3575T/2849A/2763C/1082G/819T is associated
with susceptibility, although the three distal SNPs were
sufficient to capture the information.18 There is probably a
need to verify the interaction of more extended IL10 SNP
haplotypes with the disease, and a search for new genes and
SNPs that have interplay with IL10 SNPs.
Although IL-2, IFN-g, IL-6, and TGF-b1 cytokines present
proinflammatory and anti-inflammatory characteristics in
leprosy immunopathogenesis,12,34 analysis of polymorphisms
that were previously associated with production of these
cytokines did not show differences, even in subgroups. In
this study, however, the effect of these polymorphisms on
cytokine production in patients and control subjects was not
investigated.
In summary, the present study provides consistent evi-
dence for the involvement of TNF genes in susceptibility to
leprosy. The G!A substitution at position 308 in the TNF
promoter region may be involved in different CMI in leprosy
patients due to its influence on the production of TNF-a.
However, establishment of the infection and disease devel-
opment may be conditioned by other immunological and
genetic factors. Therefore, further studies of other poly-
morphic immunoregulatory genes are needed to understand
the immune mechanism of susceptibility or resistance to
leprosy.
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